Advertisement

Anti-inflammatory Therapies for Sensorineural Hearing Loss

  • Alanna M. Windsor
  • Michael J. Ruckenstein
Chapter

Abstract

Anti-inflammatory and immunosuppressive therapies have been widely employed in the treatment of sensorineural hearing loss in the context of autoimmune inner ear disease (AIED) and idiopathic sudden sensorineural hearing loss (ISSHL). While steroids are the mainstay of treatment for these disorders, numerous other therapies, including cyclophosphamide, methotrexate, azathioprine, rituximab, anakinra, anti- TNF-α agents, and plasmapharesis have been investigated. Here we will describe the most commonly-studied of these immune-modulating therapies and review the evidence for their efficacy in the treatment of inner ear disorders, focusing on AIED and ISSHL. Further investigation of the potential inflammatory mechanisms mediating these forms of sensorineural hearing loss may ultimately identify targets for future treatments.

Keywords

Sensorineural hearing loss Autoimmune inner ear disease Corticosteroids Immunomodulation Sudden hearing loss 

References

  1. Agarwal L, Pothier DD. Vasodilators and vasoactive substances for idiopathic sudden sensorineural hearing loss. Cochrane Database Syst Rev. 2009;4:CD003422.Google Scholar
  2. Alexander TH, Weisman MH, Derebery JM, Espeland MA, Gantz BJ, Gulya AJ, et al. Safety of high-dose corticosteroids for the treatment of autoimmune inner ear disease. Otol Neurotol. 2009;30(4):443–8.CrossRefPubMedGoogle Scholar
  3. Alpa M, Bucolo S, Beatrice F, Giachino O, Roccatello D. Apheresis as rescue therapy in a severe case of sudden hearing loss. Int J Artif Organs. 2011;34(7):589–92.CrossRefPubMedGoogle Scholar
  4. André R, Corlieu P, Crabol Y, Cohen P, Guillevin L. Infliximab reverses progressive deafness. Presse Med. 2015;44(6 Pt 1):675–7.CrossRefPubMedGoogle Scholar
  5. Angeli SI, Abi-Hachem RN, Vivero RJ, Telischi FT, Machado JJ. L-N-acetylcysteine treatment is associated with improved hearing outcome in sudden idiopathic sensorineural hearing loss. Acta Otolaryngol. 2012;132(4):369–76.CrossRefPubMedGoogle Scholar
  6. Berrettini S, Ferri C, Ravecca F, LaCivita L. Progressive sensorineural hearing impairment in systemic vasculitides. Semin Arthritis Rheum. 1998;27(5):301–18.CrossRefPubMedGoogle Scholar
  7. Brant JA, Eliades SJ, Ruckenstein MJ. Systematic review of treatments for autoimmune inner ear disease. Otol Neurotol. 2015;36(10):1585–92.CrossRefPubMedGoogle Scholar
  8. Brookes GB, Newland AC. Plasma exchange in the treatment of immune complex-associated sensorineural deafness. J Laryngol Otol. 1986;100(1):25–33.CrossRefPubMedGoogle Scholar
  9. Broughton SS, Meyerhoff WE, Cohen SB. Immune-mediated inner ear disease: 10-year experience. Semin Arthritis Rheum. 2004;34(2):544–8.CrossRefPubMedGoogle Scholar
  10. Byl FM. Seventy-six cases of presumed sudden hearing loss occurring in 1973: prognosis and incidence. Laryngoscope. 1977;87(5 Pt 1):817–25.CrossRefPubMedGoogle Scholar
  11. Chen C-Y, Halpin C, Rauch SD. Oral steroid treatment of sudden sensorineural hearing loss: a ten year retrospective analysis. Otol Neurotol. 2003;24(5):728.CrossRefPubMedGoogle Scholar
  12. Clements MR, Mistry CD, Keith AO, Ramsden RT. Recovery from sensorineural deafness in Wegener’s granulomatosis. J Laryngol Otol. 1989;103(5):515–8.CrossRefPubMedGoogle Scholar
  13. Cohen S, Shoup A, Weisman MH, Harris J. Etanercept treatment for autoimmune inner ear disease: results of a pilot placebo-controlled study. Otol Neurotol. 2005;26(5):903–7.CrossRefPubMedGoogle Scholar
  14. Cohen S, Roland P, Shoup A, Lowenstein M, Silverstein H, Kavanaugh A, et al. A pilot study of rituximab in immune-mediated inner ear disease. Audiol Neurootol. 2011;16(4):214–21.CrossRefPubMedGoogle Scholar
  15. Conlin AE, Parnes LS. Treatment of sudden sensorineural hearing loss: II. A meta-analysis. Arch Otolaryngol Head Neck Surg. 2007;133(6):582–6.CrossRefPubMedGoogle Scholar
  16. Crane RA, Camilon M, Nguyen S, Meyer TA. Steroids for treatment of sudden sensorineural hearing loss: a meta-analysis of randomized controlled trials. Laryngoscope. 2015;125(1):209–17.CrossRefPubMedGoogle Scholar
  17. Derebery MJ, Fisher LM, Voelker CCJ, Calzada A. An open label study to evaluate the safety and efficacy of intratympanic golimumab therapy in patients with autoimmune inner ear disease. Otol Neurotol. 2014;35(9):1515–21.CrossRefPubMedGoogle Scholar
  18. Di Leo E, Coppola F, Nettis E, Vacca A, Quaranta N. Late recovery with cyclosporine-A of an auto-immune sudden sensorineural hearing loss. Acta Otorhinolaryngol Ital. 2011;31(6):399–401.PubMedGoogle Scholar
  19. Dowd A, Rees WD. Treatment of sensorineural deafness associated with ulcerative colitis. Br Med J (Clin Res Ed). 1987;295(6589):26.CrossRefGoogle Scholar
  20. Elidan J, Cohen E, Levi H. Effect of cyclosporine A on the hearing loss in Behçet’s disease. Ann Otol Rhinol Laryngol. 1991;100(6):464–8.CrossRefPubMedGoogle Scholar
  21. Fetterman BL, Saunders JE, Luxford WM. Prognosis and Treatment of Sudden Sensorineural Hearing Loss. Otol Neurotol. 1996;17(4):529.Google Scholar
  22. Flammer JR, Rogatsky I. Minireview: glucocorticoids in autoimmunity: unexpected targets and mechanisms. Mol Endocrinol. 2011;25(7):1075–86.CrossRefPubMedPubMedCentralGoogle Scholar
  23. García-Berrocal JR, Ramírez-Camacho R, Millán I, Górriz C, Trinidad A, Arellano B, et al. Sudden presentation of immune-mediated inner ear disease: characterization and acceptance of a cochleovestibular dysfunction. J Laryngol Otol. 2003;117(10):775–9.CrossRefPubMedGoogle Scholar
  24. García-Berrocal JR, Ibáñez A, Rodríguez A, González-García JÁ, Verdaguer JM, Trinidad A, et al. Alternatives to systemic steroid therapy for refractory immune-mediated inner ear disease: a physiopathologic approach. Eur Arch Otorhinolaryngol. 2006;263(11):977–82.CrossRefPubMedGoogle Scholar
  25. Glasscock ME, Nechtman C, Altenau M. Sudden loss of hearing: a medical emergency. South Med J. 1971;64(12):1485–9.CrossRefPubMedGoogle Scholar
  26. Gulleroglu K, Baskin E, Aydin E. Hearing status in pediatric renal transplant recipients. Exp Clin Transplant. 2015;13(4):324–8.PubMedGoogle Scholar
  27. Hamblin TJ, Mufti GJ, Bracewell A. Severe deafness in systemic lupus erythematosus: its immediate relief by plasma exchange. Br Med J (Clin Res Ed). 1982;284(6326):1374.CrossRefGoogle Scholar
  28. Han CS, Park JR, Boo SH, Jo JM. Clinical efficacy of initial intratympanic steroid treatment on sudden sensorineural hearing loss with diabetes. Otolaryngol Head Neck Surg. 2009;141(5):572–8.CrossRefPubMedGoogle Scholar
  29. Harris JP, Sharp PA. Inner ear autoantibodies in patients with rapidly progressive sensorineural hearing loss. Laryngoscope. 1990;100(5):516–24.CrossRefPubMedGoogle Scholar
  30. Harris JP, Weisman MH, Derebery JM, Espeland MA, Gantz BJ, Gulya AJ, et al. Treatment of corticosteroid-responsive autoimmune inner ear disease with methotrexate: a randomized controlled trial. JAMA. 2003;290(14):1875–83.CrossRefPubMedGoogle Scholar
  31. Harris DA, Mikulec AA, Carls SL. Autoimmune inner ear disease preliminary case report: audiometric findings following steroid treatments. Am J Audiol. 2013;22(1):120–4.CrossRefPubMedGoogle Scholar
  32. Hatano M, Uramoto N, Okabe Y, Furukawa M, Ito DM. Vitamin E and vitamin C in the treatment of idiopathic sudden sensorineural hearing loss. Acta Otolaryngol. 2009;128(2):116–21.CrossRefGoogle Scholar
  33. Hautefort C, Loundon N, Montchilova M, Marlin S, Garabedian EN, Ulinski T. Mycophenolate mofetil as a treatment of steroid dependent Cogan’s syndrome in childhood. Int J Pediatr Otorhinolaryngol. 2009;73(10):1477–9.CrossRefPubMedGoogle Scholar
  34. Heywood RL, Hadavi S, Donnelly S. Infliximab for autoimmune inner ear disease: case report and literature review. J Laryngol Otol. 2013;127(11):1145–7.CrossRefPubMedGoogle Scholar
  35. Hirose K, Wener MH, Duckert LG. Utility of laboratory testing in autoimmune inner ear disease. Laryngoscope. 1999;109(11):1749–54.CrossRefPubMedGoogle Scholar
  36. Hughes GB, Kinney SE, Barna BP, Calabrese LH. Practical versus theoretical management of autoimmune inner ear disease. Laryngoscope. 1984;94(6):758–67.CrossRefPubMedGoogle Scholar
  37. Keithley EM, Wang X, Barkdull GC. Tumor necrosis factor α can induce recruitment of inflammatory cells to the cochlea. Otol Neurotol. 2008;29(6):854–9.CrossRefPubMedGoogle Scholar
  38. Khalidi NA, Rebello R. Sensorineural hearing loss in systemic lupus erythematosus: case report and literature review. J Laryngol Otol. 2008;122(12):1371–6.CrossRefPubMedGoogle Scholar
  39. Kobayashi S, Fujishiro N, Sugiyama K. Systemic lupus erythematosus with sensorineural hearing loss and improvement after plasmapheresis using the double filtration method. Intern Med. 1992;31(6):778–81.CrossRefPubMedGoogle Scholar
  40. Langford CA. Complications of cyclophosphamide therapy. Eur Arch Otorhinolaryngol. 1997;254(2):65–72.CrossRefPubMedGoogle Scholar
  41. Lasak JM, Sataloff RT, Hawkshaw M. Autoimmune inner ear disease: steroid and cytotoxic drug therapy. Ear Nose Throat J. 2001;80(11):808–11.PubMedGoogle Scholar
  42. Liu YC, Rubin R, Sataloff RT. Treatment-refractory autoimmune sensorineural hearing loss: response to infliximab. Ear Nose Throat J. 2011;90(1):23–8.PubMedGoogle Scholar
  43. Lobo D, Trinidad A, García-Berrocal JR, Verdaguer JM, Ramírez-Camacho R. TNFα blockers do not improve the hearing recovery obtained with glucocorticoid therapy in an autoimmune experimental labyrinthitis. Eur Arch Otorhinolaryngol. 2006;263(7):622–6.CrossRefPubMedGoogle Scholar
  44. Loveman DM, de Comarmond C, Cepero R, Baldwin DM. Autoimmune sensorineural hearing loss: clinical course and treatment outcome. Semin Arthritis Rheum. 2004;34(2):538–43.CrossRefPubMedGoogle Scholar
  45. Luetje CM. Theoretical and practical implications for plasmapheresis in autoimmune inner ear disease. Laryngoscope. 1989;99(11):1137–46.CrossRefPubMedGoogle Scholar
  46. Luetje CM, Berliner KI. Plasmapheresis in autoimmune inner ear disease: long-term follow-up. Otol Neurotol. 1997;18(5):572.Google Scholar
  47. Marioni G, Perin N, Tregnaghi A, Bellemo B. Progressive bilateral sensorineural hearing loss probably induced by chronic cyclosporin A treatment after renal transplantation for focal glomerulosclerosis. Acta Otolaryngol. 2004;124(5):603–7.CrossRefPubMedGoogle Scholar
  48. Matsuoka AJ, Harris JP. Autoimmune inner ear disease: a retrospective review of forty-seven patients. Audiol Neurootol. 2013;18(4):228–39.CrossRefPubMedGoogle Scholar
  49. Matteson EL, Tirzaman O, Kasperbauer J, Facer GW, Beatty CW, Fabry DA, et al. Use of methotrexate for autoimmune hearing loss. Ann Otol Rhinol Laryngol. 2000;109(8):710–4.CrossRefPubMedGoogle Scholar
  50. Matteson EL, Choi HK, Poe DS, Wise C, Lowe VJ, McDonald TJ, et al. Etanercept therapy for immune-mediated cochleovestibular disorders: a multi-center, open-label, pilot study. Arthritis Rheum. 2005;53(3):337–42.CrossRefPubMedGoogle Scholar
  51. McCabe BF. Autoimmune sensorineural hearing loss. Ann Otol. 1979;88(5):585–9.Google Scholar
  52. McClelland L, Powell RJ, Birchall J. Role of ciclosporin in steroid-responsive sudden sensorineural hearing loss. Acta Otolaryngol. 2009;125(12):1356–60.CrossRefGoogle Scholar
  53. Merchant SN, Adams JC, Nadol JBJ. Pathology and pathophysiology of idiopathic sudden sensorineural hearing loss. Otol Neurotol. 2005;26(2):151.CrossRefPubMedGoogle Scholar
  54. Mirault T, Launay D, Cuisset L, Hachulla E, Lambert M, Queyrel V, et al. Recovery from deafness in a patient with Muckle-Wells syndrome treated with anakinra. Arthritis Rheum. 2006;54(5):1697–700.CrossRefPubMedGoogle Scholar
  55. Moscicki RA, Martin JES, Quintero CH, Rauch SD, Nadol JB, Bloch KJ. Serum antibody to inner ear proteins in patients with progressive hearing loss: correlation with disease activity and response to corticosteroid treatment. JAMA. 1994;272(8):611–6.CrossRefPubMedGoogle Scholar
  56. Moskowitz D, Lee KJ, Smith HW. Steroid use in idiopathic sudden sensorineural hearing loss. Laryngoscope. 1984;94(5 Pt 1):664–6.PubMedGoogle Scholar
  57. Niparko JK, Wang N-Y, Rauch SD, Russell GB, Espeland MA, Pierce JJ, et al. Serial audiometry in a clinical trial of AIED treatment. Otol Neurotol. 2005;26(5):908–17.CrossRefPubMedGoogle Scholar
  58. Orsoni JG, Laganà B, Rubino P, Zavota L, Bacciu S, Mora P. Rituximab ameliorated severe hearing loss in Cogan’s syndrome: a case report. Orphanet J Rare Dis. 2010;5(1):18.CrossRefPubMedPubMedCentralGoogle Scholar
  59. Parnes LS, Sun AH, Freeman DJ. Corticosteroid pharmacokinetics in the inner ear fluids: an animal study followed by clinical application. Laryngoscope. 1999;109(S91):1–17.CrossRefPubMedGoogle Scholar
  60. Pathak S, Goldofsky E, Vivas EX, Bonagura VR, Vambutas A. IL-1β Is overexpressed and aberrantly regulated in corticosteroid nonresponders with autoimmune inner ear disease. J Immunol. 2011;186(3):1870–9.CrossRefPubMedPubMedCentralGoogle Scholar
  61. Plester D, Soliman AM. Autoimmune hearing loss. Otol Neurotol. 1989;10(3):188.Google Scholar
  62. Rahman MU, Poe DS, Choi HK. Etanercept therapy for immune-mediated cochleovestibular disorders: preliminary results in a pilot study. Otol Neurotol. 2001;22(5):619.CrossRefPubMedGoogle Scholar
  63. Rauch SD. Clinical Management of Immune-mediated Inner-ear Disease. Ann N Y Acad Sci. 1997;830(1):203–10.CrossRefPubMedGoogle Scholar
  64. Rauch SD, Halpin CF, Antonelli PJ, Babu S, Carey JP, Gantz BJ, et al. Oral vs intratympanic corticosteroid therapy for idiopathic sudden sensorineural hearing loss: a randomized trial. JAMA. 2011;305(20):2071–9.CrossRefPubMedGoogle Scholar
  65. Rifai K, Bahr MJ, Cantz T, Klempnauer J. Severe hearing loss after liver transplantation. Transplant Proc. 2005;37(4):1918–9.CrossRefPubMedGoogle Scholar
  66. Ruckenstein MJ. Autoimmune inner ear disease. Curr Opin Otolaryngol Head Neck Surg. 2004;12(5):426.CrossRefPubMedGoogle Scholar
  67. Ruckenstein MJ, Hu L. Antibody deposition in the stria vascularis of the MRL-Faslpr mouse. Hear Res. 1999;127(1–2):137–42.CrossRefPubMedGoogle Scholar
  68. Ruckenstein MJ, Sarwar A, Hu L, Shami H, Marion TN. Effects of immunosuppression on the development of cochlear disease in the MRL-Fas Mouse. Laryngoscope. 1999;109(4):626–30.CrossRefPubMedGoogle Scholar
  69. Ruckenstein MJ, Mount RJ, Harrison RV. The MRL-lpr/lpr mouse: a potential model of autoimmune inner ear disease. Acta Otolaryngol. 2009;113(2):160–5.CrossRefGoogle Scholar
  70. Ryan AF, Harris JP, Keithley EM. Immune-mediated hearing loss: basic mechanisms and options for therapy. Acta Otolaryngol. 2009;122(5):38–43.CrossRefGoogle Scholar
  71. Sabbagh El NG, Sewitch MJ, Bezdjian A, Daniel SJ. Intratympanic dexamethasone in sudden sensorineural hearing loss: a systematic review and meta-analysis. Laryngoscope. 2016;88(suppl):524.Google Scholar
  72. Salley LH, Grimm M, Sismanis A, Spencer RF, Wise CM. Methotrexate in the management of immune mediated cochleovesitibular disorders: clinical experience with 53 patients. J Rheumatol. 2001;28(5):1037–40.PubMedGoogle Scholar
  73. Sano H, Kamijo T, Ino T, Okamoto M. Edaravone, a free radical scavenger, in the treatment of idiopathic sudden sensorineural hearing loss with profound hearing loss. Auris Nasus Larynx. 2010;37(1):42–6.CrossRefPubMedGoogle Scholar
  74. Saraçaydin A, Katircioğlu S, Katircioğlu S, Karatay MC. Azathioprine in combination with steroids in the treatment of autoimmune inner-ear disease. J Int Med Res. 2016;21(4):192–6.CrossRefGoogle Scholar
  75. Satoh H, Firestein GS, Billings PB, Harris JP, Keithley EM. Tumor necrosis factor-α, an initiator, and etanercept, an inhibitor of cochlear inflammation. Laryngoscope. 2002;112(9):1627–34.CrossRefPubMedGoogle Scholar
  76. Scheinfeld N. A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab. J Dermatol Treat. 2009;15(5):280–94.CrossRefGoogle Scholar
  77. Sharaf K, Ihler F, Bertlich M, Reichel CA, Berghaus A, Canis M. Tumor necrosis factor-induced decrease of cochlear blood flow can be reversed by etanercept or JTE-013. Otol Neurotol. 2016;37(7):e203–8.CrossRefPubMedGoogle Scholar
  78. Sismanis A, Wise CM, Johnson GD. Methotrexate management of immune-mediated cochleovestibular disorders. Otolaryngol Head Neck Surg. 2016.Google Scholar
  79. Slattery WH, Fisher LM, Iqbal Z. Oral steroid regimens for idiopathic sudden sensorineural hearing loss. Otolaryngol Head Neck Surg. 2005;132(1):5–10.CrossRefPubMedGoogle Scholar
  80. Stachler RJ, Chandrasekhar SS, Archer SM, Rosenfeld RM, Schwartz SR, Barrs DM, et al. Clinical practice guideline: sudden hearing loss. Otolaryngol Head Neck Surg. 2012;146(3 Suppl):S1–S35.CrossRefPubMedGoogle Scholar
  81. Suckfüll M. Fibrinogen and LDL apheresis in treatment of sudden hearing loss: a randomised multicentre trial. Lancet. 2002;360(9348):1811–7.CrossRefPubMedGoogle Scholar
  82. Trune DR, Canlon B. Corticosteroid therapy for hearing and balance disorders. Anat Rec. 2012;295(11):1928–43.CrossRefGoogle Scholar
  83. Trune DR, Wobig RJ, Kempton JB, Hefeneider SH. Steroid treatment in young MRL.MpJ-Faslpr autoimmune mice prevents cochlear dysfunction. Hear Res. 1999a;137(1–2):167–73.CrossRefPubMedGoogle Scholar
  84. Trune DR, Wobig RJ, Kempton JB, Hefeneider SH. Steroid treatment improves cochlear function in the MRL.MpJ-Faslpr autoimmune mouse. Hear Res. 1999b;137(1–2):160–6.CrossRefPubMedGoogle Scholar
  85. Trune DR, Kempton JB, Gross ND. Mineralocorticoid receptor mediates glucocorticoid treatment effects in the autoimmune mouse ear. Hear Res. 2006;212(1–2):22–32.CrossRefPubMedGoogle Scholar
  86. Vambutas A, DeVoti J, Goldofsky E, Gordon M, Lesser M, Bonagura V. Alternate splicing of interleukin-1 receptor type II (IL1R2) in vitro correlates with clinical glucocorticoid responsiveness in patients with AIED. PLoS One. 2009;4(4):e5293.CrossRefPubMedPubMedCentralGoogle Scholar
  87. Vambutas A, Lesser M, Mullooly V, Pathak S, Zahtz G, Rosen L, et al. Early efficacy trial of anakinra in corticosteroid-resistant autoimmune inner ear disease. J Clin Invest. 2014;124(9):4115–22.CrossRefPubMedPubMedCentralGoogle Scholar
  88. Van Wijk F, Staecker H, Keithley E, Lefebvre PP. Local perfusion of the tumor necrosis factor α blocker infliximab to the inner ear improves autoimmune neurosensory hearing loss. Audiol Neurootol. 2006;11(6):357–65.CrossRefPubMedGoogle Scholar
  89. Veldman JE, Hanada T, Meeuwsen F. Diagnostic and therapeutic dilemmas in rapidly progressive sensorineural hearing loss and sudden deafness a reappraisal of immune reactivity in inner ear disorders. Acta Otolaryngol. 1993;113(3):303–6.CrossRefPubMedGoogle Scholar
  90. Vergles JM, Radic M, Kovacic J, Salamon L. Successful use of adalimumab for treating rheumatoid arthritis with autoimmune sensorineural hearing loss: two birds with one stone. J Rheumatol. 2010;37(5):1080–1.CrossRefGoogle Scholar
  91. Wang X, Truong T, Billings PB, Harris JP, Keithley EM. Blockage of immune-mediated inner ear damage by etanercept. Otol Neurotol. 2003;24(1):52.CrossRefPubMedGoogle Scholar
  92. Westerlaken BO, Stokroos RJ, Wit HP, Dhooge IJM, Albers FWJ. Treatment of idiopathic sudden sensorineural hearing loss with antiviral therapy: a prospective, randomized, double-blind clinical trial. Ann Otol Rhinol Laryngol. 2016;112(11):993–1000.CrossRefGoogle Scholar
  93. Whitaker S. Idiopathic sudden hearing loss. Otol Neurotol. 1980;1(3):180.Google Scholar
  94. Wilson WR, Byl FM, Laird N. The efficacy of steroids in the treatment of idiopathic sudden hearing loss: a double-blind clinical study. Arch Otolaryngol. 1980;106(12):772–6.CrossRefPubMedGoogle Scholar
  95. Wilson WR, Stathopoulos D, O’Leary S. Steroids for idiopathic sudden sensorineural hearing loss. Cochrane Database Syst Rev. 2006;7:CD003998.Google Scholar
  96. Wu H-P, Chou Y-F, Yu S-H, Wang C-P, Hsu C-J, Chen P-R. Intratympanic steroid injections as a salvage treatment for sudden sensorineural hearing loss: a randomized, double-blind, placebo-controlled study. Otol Neurotol. 2011;32(5):774–9.CrossRefPubMedGoogle Scholar
  97. Yamazaki T, Masumoto J, Agematsu K, Sawai N, Kobayashi S, Shigemura T, et al. Anakinra improves sensory deafness in a Japanese patient with Muckle-Wells syndrome, possibly by inhibiting the cryopyrin inflammasome. Arthritis Rheum. 2008;58(3):864–8.CrossRefPubMedGoogle Scholar
  98. Yang GSY, Song H-T, Keithley EM, Harris JP. Intratympanic immunosuppressives for prevention of immune-mediated sensorineural hearing loss. Otol Neurotol. 2000;21(4):499.Google Scholar
  99. Zadeh MH, Storper IS, Spitzer JB. Diagnosis and treatment of sudden-onset sensorineural hearing loss: a study of 51 patients. Otolaryngol Head Neck Surg. 2003;128(1):92–8.CrossRefPubMedGoogle Scholar
  100. Zeitoun H, Beckman JG, Arts HA. Corticosteroid response and supporting cell antibody in autoimmune hearing loss. Arch Otolaryngol Head Neck Surg. 2005;131(8):665–72.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Otorhinolaryngology-Head and Neck SurgeryUniversity of PennsylvaniaPhiladelphiaUSA

Personalised recommendations